Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell - The Niche
UC Davis professor discusses 4 stem cell stocks from biotechs that have really struggled in recent years in the context of the wider industry.
Professor Paul Knoepfler, Ph.D.
